Additional file 1: Figure S1. HDAC inhibitors upregulate NKG2D ligands. (a–d) MICA and MICB mRNA levels in RPMI8226 and U266 cells exposed to panobinostat/ACY-1215. Experiments were performed in triplicate (n = 3). (*p < 0.05, **p < 0.01, “ns” indicates no significant difference.) (e) The ratio of mRNA expression for MICA and MICB between cells exposed to panobinostat, romidepsin, ACY-1215 and those exposed to DMSO for 0 h and 4 h. (f) IKZF1 mRNA levels in U266 cells exposed to panobinostat. (**p < 0.01) (g-h) Prognostic value of NKG2D ligand expression based on MM patient clinical trial data.
Funding
Janssen Pharmaceuticals Bristol-Myers Squibb Okinaka Memorial Institute for Medical Research Japan Society for the Promotion of Science Takeda Pharmaceutical Company AbbVie MSD K.K.